Article Title: Appeals Court Says No to Cap on Indirect Costs in NIH Grants
Publication Date: January 6, 2026
In recent news, the U.S. Court of Appeals for the First Circuit upheld a permanent injunction on January 5, 2026, that quashed the National Institutes of Health (NIH)’s attempt to impose a 15% cap on indirect costs in all its grants. The decision overturns an NIH supplemental guidance and rejects the cap both retroactively and prospectively. The cap’s future now depends on whether the U.S. Supreme Court decides to intervene and reverse the decision.
The court’s ruling is significant as it determines the cost coverage policy for indirect expenses like administrative overheads, utilities, and facility maintenance associated with scientific research funded by NIH grants. By upholding the injunction, the court has effectively prevented a unilateral reduction in funding, which could potentially have had a severe impact on scientific institutions reliant on these grants.
The controversial 15% cap proposed by the NIH had ramifications for the entirety of the life sciences industry, potentially affecting a broad spectrum of biomedical research activities and the institutions supporting them. By vacating this cap, the court has, in essence, preserved the status quo for research institutions and their budgets.
For the biotech industry, the court’s decision implies greater fiscal stability, at least in the near term. The proposed cap could have introduced considerable uncertainty and financial challenges for entities heavily dependent on NIH grants. With the maintenance of current funding levels, the industry can continue to invest in innovative research and development without the impending worry of budgetary constraints.
This development is critical not just for the companies and institutions directly receiving NIH funds, but also for a wider spectrum of stakeholders, including investors, innovators, and biotech executives. Consistency in funding indirectly impacts the ability to plan long-term strategic initiatives, maintain research momentum, and ultimately bring innovative treatments and solutions to the market.
Industry Informant remains committed to providing timely and accurate updates such as this, to help industry leaders navigate the constantly evolving landscape of biotech and life sciences. We thank our readers for their trust and we pledge to continue offering in-depth analysis and information to aid your decision-making processes.
